欧洲-话题@MedSci

#欧洲#

592篇内容 | 6052人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1339023, encodeId=dce6133902366, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Diabetic Med：黑人，南亚和欧洲白人少数民族的握力和糖尿病患病率之间的关系, objectType=article, longId=111583, objectId=996411158394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996411158394, replyNumber=0, likeNumber=56, createdTime=2017-09-02, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996411158394, moduleTitle=Diabetic Med：黑人，南亚和欧洲白人少数民族的握力和糖尿病患病率之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=996411158394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339022, encodeId=8ae1133902274, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲卒中组织(ESO)关于无活动能力的急性缺血性卒中患者静脉血栓栓塞的预防指南（翻译版）, objectType=article, longId=110759, objectId=3ace110e59c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ace110e59c6, replyNumber=0, likeNumber=28, createdTime=2017-08-26, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ace110e59c6, moduleTitle=欧洲卒中组织(ESO)关于无活动能力的急性缺血性卒中患者静脉血栓栓塞的预防指南（翻译版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ace110e59c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339021, encodeId=5490133902140, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=CRISPR专利之争出现新对手：默克集团子公司获欧洲专利, objectType=article, longId=108234, objectId=7dfe10823458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dfe10823458, replyNumber=0, likeNumber=0, createdTime=2017-08-11, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dfe10823458, moduleTitle=CRISPR专利之争出现新对手：默克集团子公司获欧洲专利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dfe10823458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339020, encodeId=c32b13390200d, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲重症监护医学会危重症患者早期肠内营养临床实践指南, objectType=article, longId=107943, objectId=d56010e94333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d56010e94333, replyNumber=0, likeNumber=29, createdTime=2017-08-08, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d56010e94333, moduleTitle=欧洲重症监护医学会危重症患者早期肠内营养临床实践指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d56010e94333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339019, encodeId=4ae7133901991, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲专利局将批准默克的CRISPR技术专利申请, objectType=article, longId=107738, objectId=be5510e738c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be5510e738c0, replyNumber=0, likeNumber=83, createdTime=2017-08-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be5510e738c0, moduleTitle=欧洲专利局将批准默克的CRISPR技术专利申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be5510e738c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339018, encodeId=2a791339018a4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=【盘点】欧洲泌尿外科学《European Urology》期刊七月文章一览, objectType=article, longId=107363, objectId=fc9110e36327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc9110e36327, replyNumber=0, likeNumber=91, createdTime=2017-08-03, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc9110e36327, moduleTitle=【盘点】欧洲泌尿外科学《European Urology》期刊七月文章一览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc9110e36327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339017, encodeId=09f2133901ea4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Rheumatology (Oxford)：注意啦！欧洲不同国家患者抗骨质疏松药物偏好不同, objectType=article, longId=107249, objectId=c78710e249af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78710e249af, replyNumber=0, likeNumber=62, createdTime=2017-08-02, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78710e249af, moduleTitle=Rheumatology (Oxford)：注意啦！欧洲不同国家患者抗骨质疏松药物偏好不同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78710e249af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339016, encodeId=add51339016c3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Lancet Oncol：欧洲罕见肿瘤的负担及治疗, objectType=article, longId=104652, objectId=c9601046520d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9601046520d, replyNumber=0, likeNumber=54, createdTime=2017-07-07, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9601046520d, moduleTitle=Lancet Oncol：欧洲罕见肿瘤的负担及治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9601046520d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339015, encodeId=ca88133901519, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Lancet：欧洲稀发肿瘤的集中治疗和负担, objectType=article, longId=104645, objectId=bcfe1046456a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcfe1046456a, replyNumber=0, likeNumber=64, createdTime=2017-07-07, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcfe1046456a, moduleTitle=Lancet：欧洲稀发肿瘤的集中治疗和负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcfe1046456a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339014, encodeId=517b13390145d, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲已启动高胆固醇血症疫苗1期临床试验, objectType=article, longId=103594, objectId=c94110359404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c94110359404, replyNumber=0, likeNumber=79, createdTime=2017-06-29, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c94110359404, moduleTitle=欧洲已启动高胆固醇血症疫苗1期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c94110359404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339013, encodeId=353b1339013f3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=LANCET：欧洲晚期肾病儿童接受肾脏替代治疗的死亡率差异原因分析, objectType=article, longId=99752, objectId=662b99e521c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662b99e521c, replyNumber=0, likeNumber=75, createdTime=2017-05-28, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662b99e521c, moduleTitle=LANCET：欧洲晚期肾病儿童接受肾脏替代治疗的死亡率差异原因分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662b99e521c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339012, encodeId=1a9913390121d, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=【精品】欧洲血脂异常管理指南（英文版、中文版及热点解读）, objectType=article, longId=99574, objectId=947e995e458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=947e995e458, replyNumber=0, likeNumber=78, createdTime=2017-05-26, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=947e995e458, moduleTitle=【精品】欧洲血脂异常管理指南（英文版、中文版及热点解读）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=947e995e458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339011, encodeId=31e3133901197, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=关注胃部健康，权威专家解读欧洲胃肠疾病周, objectType=article, longId=96590, objectId=6c8396590ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c8396590ef, replyNumber=0, likeNumber=74, createdTime=2017-04-22, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c8396590ef, moduleTitle=关注胃部健康，权威专家解读欧洲胃肠疾病周, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c8396590ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339010, encodeId=8d211339010b4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=【精品指南】 2016 ESC：欧洲急慢性心力衰竭指南内容要点总结, objectType=article, longId=94052, objectId=c5de9405248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5de9405248, replyNumber=0, likeNumber=62, createdTime=2017-04-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5de9405248, moduleTitle=【精品指南】 2016 ESC：欧洲急慢性心力衰竭指南内容要点总结, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5de9405248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339009, encodeId=945a133900960, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法, objectType=article, longId=94071, objectId=2032940e105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2032940e105, replyNumber=0, likeNumber=77, createdTime=2017-03-31, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2032940e105, moduleTitle=百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2032940e105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339008, encodeId=48101339008af, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Eur Respir J: ERS（欧洲呼吸学会）/ATS（美国胸科学会）指南: COPD急性加重的管理, objectType=article, longId=93819, objectId=8d5e9381960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d5e9381960, replyNumber=0, likeNumber=60, createdTime=2017-03-30, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d5e9381960, moduleTitle=Eur Respir J: ERS（欧洲呼吸学会）/ATS（美国胸科学会）指南: COPD急性加重的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d5e9381960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339007, encodeId=49fb133900e9b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, objectType=article, longId=90445, objectId=632a904456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632a904456c, replyNumber=0, likeNumber=64, createdTime=2017-03-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632a904456c, moduleTitle=[药企软文]重磅！美罗华生物仿制药在欧洲获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632a904456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339006, encodeId=5f7d1339006c3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=强生300亿美元收购欧洲很大生物制药公司Actelion 开辟罕见病治疗领域, objectType=article, longId=88958, objectId=d61188958bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d61188958bc, replyNumber=0, likeNumber=61, createdTime=2017-02-17, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d61188958bc, moduleTitle=强生300亿美元收购欧洲很大生物制药公司Actelion 开辟罕见病治疗领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d61188958bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339005, encodeId=f33b133900510, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=重磅：吉利德乙肝药物Vemlidy获欧盟批准进入欧洲市场, objectType=article, longId=87680, objectId=871d8e68094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=871d8e68094, replyNumber=0, likeNumber=62, createdTime=2017-01-19, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=871d8e68094, moduleTitle=重磅：吉利德乙肝药物Vemlidy获欧盟批准进入欧洲市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=871d8e68094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339004, encodeId=b2ad1339004ae, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=默克在北美、中国和欧洲拓展端到端生物开发中心, objectType=article, longId=87307, objectId=2bf38e30791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bf38e30791, replyNumber=0, likeNumber=74, createdTime=2017-01-13, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bf38e30791, moduleTitle=默克在北美、中国和欧洲拓展端到端生物开发中心, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bf38e30791)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Diabetic Med：黑人，南亚和欧洲白人少数民族的握力和糖尿病患病率之间的关系

2017-09-02

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲卒中组织(ESO)关于无活动能力的急性缺血性卒中患者静脉血栓栓塞的预防指南（翻译版）

2017-08-26

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

CRISPR专利之争出现新对手：默克集团子公司获欧洲专利

2017-08-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲重症监护医学会危重症患者早期肠内营养临床实践指南

2017-08-08

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲专利局将批准默克的CRISPR技术专利申请

2017-08-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

【盘点】欧洲泌尿外科学《European Urology》期刊七月文章一览

2017-08-03

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Rheumatology (Oxford)：注意啦！欧洲不同国家患者抗骨质疏松药物偏好不同

2017-08-02

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Lancet Oncol：欧洲罕见肿瘤的负担及治疗

2017-07-07

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Lancet：欧洲稀发肿瘤的集中治疗和负担

2017-07-07

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲已启动高胆固醇血症疫苗1期临床试验

2017-06-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

LANCET：欧洲晚期肾病儿童接受肾脏替代治疗的死亡率差异原因分析

2017-05-28

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

【精品】欧洲血脂异常管理指南（英文版、中文版及热点解读）

2017-05-26

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

关注胃部健康，权威专家解读欧洲胃肠疾病周

2017-04-22

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

【精品指南】 2016 ESC：欧洲急慢性心力衰竭指南内容要点总结

2017-04-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法

2017-03-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Eur Respir J: ERS（欧洲呼吸学会）/ATS（美国胸科学会）指南: COPD急性加重的管理

2017-03-30

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

[药企软文]重磅！美罗华生物仿制药在欧洲获得批准

2017-03-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

强生300亿美元收购欧洲很大生物制药公司Actelion 开辟罕见病治疗领域

2017-02-17

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

重磅：吉利德乙肝药物Vemlidy获欧盟批准进入欧洲市场

2017-01-19

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

默克在北美、中国和欧洲拓展端到端生物开发中心

2017-01-13

科室
- - 订阅+
  - 更多科室
工具
服务